Author

Julio Pow-Sang

Moffitt Cancer Center - Cited by 10,836 - Urologic Oncology

Biography

Julio Pow-Sang is currently working in Departments of Epidemiology, Health Outcomes and Behavior, Biostatistics, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida College of Medicine, Florida, USA. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his/her valuable service towards the scientific community with his extensive research work.
Title
Cited by
Year
NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines
E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ...Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021202
267
2021
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
MJ Morris, SP Rowe, MA Gorin, L Saperstein, F Pouliot, D Josephson, ...Clinical Cancer Research 27 (13), 3674-3682, 2021202
159
2021
NCCN Guidelines® insights: prostate cancer, version 1.2023: featured updates to the NCCN guidelines
EM Schaeffer, S Srinivas, N Adra, Y An, D Barocas, R Bitting, A Bryce, ...Journal of the National Comprehensive Cancer Network 20 (12), 1288-1298, 2022202
26
2022
Patient-reported outcomes in clinical trials leading to cancer immunotherapy drug approvals from 2011 to 2018: a systematic review
H Safa, M Tamil, PE Spiess, B Manley, J Pow-Sang, SM Gilbert, F Safa, ...JNCI: Journal of the National Cancer Institute 113 (5), 532-542, 2021202
22
2021
Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and …
Z Yuan, D Fernandez, J Dhillon, J Abraham-Miranda, S Awasthi, Y Kim, ...Prostate cancer and prostatic diseases 24 (1), 140-149, 2021202
13
2021
Repeatability of quantitative imaging features in prostate magnetic resonance imaging
H Lu, NA Parra, J Qi, K Gage, Q Li, S Fan, S Feuerlein, J Pow-Sang, ...Frontiers in oncology , 551, 2020202
10
2020
Budget impact of adaptive Abiraterone therapy for castration-resistant prostate cancer
NT Mason, JM Burkett, RS Nelson, JM Pow-Sang, RA Gatenby, T Kubal, ...American Health & Drug Benefits 14 (1), 15, 2021202
10
2021
Focal bipolar radiofrequency ablation for localized prostate cancer: safety and feasibility
AM Aydin, K Gage, J Dhillon, SK Cheriyan, MA Poch, BJ Manley, R Li, ...International Journal of Urology 27 (), 882-889, 2020202
10
2020
Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study
S Rubino, Y Kim, J Zhou, J Dhilon, R Li, P Spiess, M Poch, BJ Manley, ...World journal of urology 3, 153-1547, 2021202
9
2021
Quantification and optimization of standard-of-care therapy to delay the emergence of resistant bone metastatic prostate cancer
A Araujo, LM Cook, JS Frieling, W Tan, JA Copland, M Kohli, S Gupta, ...Cancers 13 (4), 77, 2021202
6
2021
Novel transcriptomic interactions between immune content and genomic classifier predict lethal outcomes in high-grade prostate cancer
K Yamoah, S Awasthi, BA Mahal, SG Zhao, GD Grass, A Berglund, ...European urology 81 (4), 325-330, 2022202
6
2022
KLK3 SNP–SNP interactions for prediction of prostate cancer aggressiveness
HY Lin, PY Huang, CH Cheng, HY Tung, Z Fang, AE Berglund, A Chen, ...Scientific reports 11 (1), 924, 2021202
6
2021
Effects of green tea catechins on prostate cancer chemoprevention: the role of the gut microbiome
NB Kumar, S Hogue, J Pow-Sang, M Poch, BJ Manley, R Li, J Dhillon, ...Cancers 14 (16), 3988, 2022202
5
2022
Genomic testing in localized prostate cancer can identify subsets of african americans with aggressive disease
S Awasthi, GD Grass, J Torres-Roca, PAS Johnstone, J Pow-Sang, ...JNCI: Journal of the National Cancer Institute 114 (12), 166-1664, 2022202
5
2022
Effectiveness and safety of prostatic artery embolization for the treatment of lower urinary tract symptoms from benign prostatic hyperplasia in men with concurrent localized …
N Parikh, E Keshishian, B Manley, GD Grass, J Torres-Roca, D Boulware, ...Journal of vascular and interventional radiology 32 (7), 103-1061, 2021202
5
2021
Prostatic artery embolization is safe and effective for medically recalcitrant radiation-induced prostatitis
N Parikh, E Keshishian, A Sharma, M Roca, B Manley, M Poch, GD Grass, ...Advances in Radiation Oncology (), 90-909, 2020202
5
2020
TMPRSS2‐ERG fusion impacts anterior tumor location in men with prostate cancer
K Yamoah, P Lal, S Awasthi, AO Naghavi, RJ Rounbehler, T Gerke, ...The Prostate 81 (2), 109-117, 2021202
4
2021
Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity
A Hajiran, L Zemp, AM Aydin, SK Cheryian, JM Pow-Sang, J Chahoud, ...Urologic Oncology: Seminars and Original Investigations 39 (1), 72. e1-72. e5, 2021202
4
2021
Analysis of MRI radiomic pelvimetry and correlation with margin status after robotic prostatectomy.
I Youssef, M Poch, N Raghunand, J Pow-Sang, PAS JohnstoneThe Canadian Journal of Urology 29 (1), 10976-10978, 2022202
3
2022
Preliminary results from phase Ib/II neoadjuvant CG0070 and nivolumab (N) for cisplatin (C)-ineligible muscle invasive bladder cancer (MIBC).
R Li, PE Spiess, WJ Sexton, SM Gilbert, MA Poch, JM Pow-Sang, J Zhang, ...Journal of Clinical Oncology 40 (16_suppl), 4574-4574, 2022202
3
2022

Referred From: https://scholar.google.com/citations?hl=en&user=S7CV7-IAAAAJ

Cited by
Citations 10836
h-index 50
i10-index 141
Recommended Journals
Open Access Journals